Pharmaceuticals

A new partnership between Japan's Ono Pharma and US biotech Mediar aims to disrupt the massive fibro-inflammatory disease market by targeting the root cell of scarring.

Priovant's Phase 3 trial for brepocitinib in cutaneous sarcoidosis isn't just about one disease. It's a key move in Roivant's playbook to build a rare disease powerhouse.

With $60M in new funding and veteran pharma execs on board, Vedanta Biosciences is set for the pivotal last leg of its Phase 3 trial for VE303.

Actimed Therapeutics reclaims S-oxprenolol, a promising ALS drug. This isn't just a pipeline shuffle; it's a calculated move to dominate the future of muscle health.

Fosun International’s recent triple award win isn't just a PR victory. It’s a signal of a meticulously crafted strategy where ESG, AI, and financial resilience converge.

With a pill aimed at both heart disease and blindness, BioAge Labs is betting its future on fighting aging itself. Is this the dawn of a new era in medicine?

As Biofrontera preps its Q2 report, investors weigh record revenue and expanded margins against persistent losses and a critical need for cash flow breakeven.

Facing the biotech cash crunch, Context Therapeutics shelves one drug to double down on two others, a strategic pivot that secures its future into late 2027.

The hormone optimization leader's stock tumbles after Q2 results show a net loss and declining revenue, revealing the prolonged impact of its January recall.

Bristol Myers Squibb's large-scale deployment of Schrödinger's Bunsen AI isn't just a software deal; it's a strategic signal for the future of pharma R&D.

Expedition Therapeutics lands a huge Series B and starts a pivotal trial for a drug that could finally target the root cause of COPD for millions.

As Ascentage Pharma preps its mid-year report, we look beyond the balance sheet at the strategic plays and clinical trials fueling its global oncology ambitions.

A quiet South Korean biotech is shaking up the drug delivery landscape. Alteogen's latest deal signals a major shift as Big Pharma races to make treatments better.

Eton Pharmaceuticals' new deal for ASN-001 is more than a pipeline buy; it's a calculated maneuver to capture the entire infantile hemangioma treatment space.

Compass Pathways is racing towards a 2027 launch for its psilocybin therapy. But can it navigate the complex regulatory and commercial hurdles to deliver on its promise?

A revenue dip masks a calculated pivot. UTHR is betting its future not just on new drugs, but on a revolutionary plan to manufacture human organs.

As Everest Medicines preps its H1 2026 results, investors are watching for more than just profit, focusing on its pivot to a global innovation engine.

Attovia Therapeutics’ successful IPO injects massive capital into its ambitious pipeline, but can its novel multi-specific antibody platform outmaneuver giants?

With a fortified balance sheet and a strategic pivot, OnKure Therapeutics is betting that precision and selectivity will conquer a competitive drug market.

Entropy Neurodynamics launches a world-first 'basket study' for its IV psilocin, a high-stakes bet that could redefine mental health treatment pipelines.